Cardiology

The approval indicates the SGLT2 inhibitor for reducing risk of CV death and hospitalizations for heart failure in adults with heart failure.

An expert panel discusses where bempedoic acid currently fits into the treatment of hypercholesterolemia.

What pharmacists and providers need to know to counsel patients on when discussing the use of prescription or over-the-counter fish oil supplement as treatment for dyslipidemia and hypertriglyceridemia.

Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.

An overview of the REDUCE-IT trial of icosapent ethyl for the management of triglycerides and prevention of cardiovascular events.

American Heart Month is a great time for pharmacists to educate the public about their contributions to managing patients with cardiovascular disease.

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.

A poster presented at the American Diabetes Association Virtual 81st Scientific Sessions highlighted the effect of a physician-pharmacist collaborative management team in diabetes preventative care services.

The FDA approved Pradaxa (dabigatran etexilate) to treat venous thromboembolism in children aged 3 months to less than 12 years.

Blood-brain barrier crossing medicines have shown memory benefits in elderly patients, according to a new analysis.

Community model for hypertension management drives increased access, better outcomes for patients.

Individuals with prediabetes may be at increased risk of suffering an adverse cardiovascular event.

A new drug review for vericiguat, indicated for heart failure, reports efficacy and safety data.

The study incorporated diverse populations to determine the association between diets with a high glycemic index and cardiovascular disease risk.

Hispanic and Latino adults have a high prevalence of cardiovascular risk factors, but many are receiving inadequate treatment.

The American Heart Association published a special issue to discuss current research in cardiovascular disease and outcomes in women.

Investigators used MRI scans of the heart to identify whether heart injury was caused by COVID-19 infection.

New clinical practice guidelines call for lowering blood pressure levels down to 120 mmHg systolic for those with chronic kidney disease.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Novartis’ sacubitril/valsartan (Entresto) is now indicated for use in the treatment of chronic heart failure.

The American Heart Association’s recent scientific statement found that mental health impacts risk factors for heart disease.

Insulin resistance and type 2 diabetes were major contributors to premature coronary heart disease, according to the study results.

The American Heart Association (AHA) is urging those with heart conditions and those who are at risk for cardiovascular disease to receive the COVID-19 vaccine.

Pharmacists can help patients through education, therapy, and lifestyle modifications.